Both FDA-approved drugs significantly increased ASL pH in CF control epithelia (Fig. 5C), but this effect was absent in SLC26A4 KO epithelia, suggesting a direct involvement of this anion exchanger in the response. Here, SLC26A4 is linked to cystic fibrosis.